AGT G-6A

AGT G-6A — The Promoter Switch That Turns Up Blood Pressure

Angiotensinogen (AGT) | the precursor protein for the entire renin-angiotensin-aldosterone system (RAAS) is produced primarily in the liver and released into the bloodstream, where renin cleaves it to angiotensin I. Angiotensin I is then converted by ACE into angiotensin II — the potent vasoconstrictor that raises blood pressure, promotes sodium retention, and drives cardiovascular remodeling. The rs5051 (G-6A) variant sits in the core promoter of the AGT gene, just 6 base pairs upstream of the transcription start site, where it acts as a molecular volume knob for angiotensinogen production.

The Mechanism

The AGT gene sits on the minus (reverse) strand of chromosome 1. In minus-strand notation, the variant is described as G-6A: a guanine-to-adenine substitution at position −6 relative to the transcription start. On the sequencing plus strand (what genome files report), this corresponds to a C-to-T change at rs5051.

The −6 position lies within the core promoter where transcription factors assemble to initiate RNA synthesis. Luciferase reporter assays | a standard molecular technique measuring how powerfully a DNA sequence drives gene expression demonstrate that the A allele at −6 (plus-strand T) drives significantly higher AGT transcriptional activity than the G allele — up to 68.6% more mRNA output. The adenine at this position likely alters the binding affinity of a transcription factor at or near the core promoter, sustaining higher rates of AGT mRNA synthesis. More AGT mRNA → more angiotensinogen protein → more substrate for renin → more angiotensin I → more angiotensin II → chronically elevated blood pressure.

The Evidence

Powell et al. 2024 | Analysis of the combined effect of rs699 and rs5051 on angiotensinogen expression and hypertension. Chronic Dis Transl Med, 2024 analyzed 311,004 UK Biobank participants and found that rs5051 C>T associates with a 0.35 mmHg increase in systolic blood pressure per T allele (p<0.001). The effect was fourfold larger in Black participants (1.17 mmHg per allele, p=0.032) than in White participants (0.25 mmHg), consistent with the T allele's much higher frequency in African-ancestry populations. The study also confirmed in cell models that rs5051 T increases AGT transcription by up to 68.6% through altered transcription factor binding.

Gu et al. 2011 | A-6G and A-20C Polymorphisms in the Angiotensinogen Promoter and Hypertension Risk in Chinese: A Meta-Analysis. PLoS One, 2011 pooled 15 studies comprising 3,442 hypertensive patients and 3,058 controls. Paradoxically, in Han Chinese populations where the T allele is very common (~83%), the dominant model showed the T (A at −6) allele was associated with lower hypertension risk (OR=0.71, 95%CI 0.57–0.87, p=0.001). Sex-specific analysis found protection was significant in women (OR=0.73) but not men. This apparently counterintuitive result likely reflects population-level confounding from linkage disequilibrium with other AGT haplotype variants, a pattern that differs between East Asian and European populations.

Chen et al. 2012 | Promoter G-6A polymorphism associated with non-familial sick sinus syndrome. PLoS One, 2012 confirmed that the A allele at −6 produces higher AGT promoter transcriptional activity in luciferase assays and found that the G allele (lower AGT expression) was associated with sick sinus syndrome susceptibility — the complement of elevated-AGT effects on blood pressure.

Li et al. 2014 | AGT polymorphisms and essential hypertension in Northern Han Chinese. Angiology, 2014 found significantly different A-6G genotype distributions between 652 hypertensive patients and 780 controls (p<0.05) in a Chinese cohort, providing additional population-level evidence of the variant's role in essential hypertension susceptibility.

Practical Actions

Because rs5051 is tightly linked (r²=0.94) with rs699 (M235T), the two variants are almost always inherited together. Their combined effect on AGT expression and blood pressure is larger than either alone. Individuals carrying the T allele at rs5051 who also carry the G allele at rs699 have the highest angiotensinogen-driven blood pressure elevation.

For T allele carriers, the primary actionable implication is that a component of your blood pressure tends to be driven by genetically elevated angiotensinogen substrate supply to the RAAS. This means that RAAS-blocking medications — ACE inhibitors and angiotensin receptor blockers (ARBs) — target the precise upstream mechanism and may be particularly effective for blood pressure management in individuals with this genotype.

Dietary sodium restriction also exerts a larger effect on angiotensinogen-mediated blood pressure, since high sodium intake stimulates RAAS activity, compounding the elevated substrate supply.

Interactions

rs5051 and rs699 (AGT M235T) are almost universally co-inherited (r²=0.94) and function as a functional haplotype. rs5051 affects AGT transcription; rs699 changes the angiotensinogen protein sequence (Met235Thr), which independently affects angiotensinogen protein stability and plasma levels. The haplotype carrying rs5051-T + rs699-G produces the highest combined elevation in plasma angiotensinogen.

The RAAS as a whole is governed by several interacting variants: AGTR1 rs5186 (AT1 receptor, 3' UTR), ACE I/D rs4340 (ACE enzyme level), and CYP11B2 rs1799998 (aldosterone synthase). Individuals carrying multiple RAAS-elevating variants across these genes show compounding hypertension risk beyond the individual variant effects.